|Bid||0.00 x 1400|
|Ask||0.00 x 1300|
|Day's Range||43.50 - 44.32|
|52 Week Range||41.23 - 58.37|
|Beta (3Y Monthly)||1.14|
|PE Ratio (TTM)||17.94|
|Forward Dividend & Yield||1.27 (2.82%)|
|1y Target Est||47.20|
The government requires hedge funds and wealthy investors with over a certain portfolio size to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings discloses the funds’ positions on June […]
A/S is cutting costs and reallocating research and development spending as it faces price pressures in the U.S., its biggest market. Four hundred jobs will be eliminated in the company’s research and development unit. Most of the savings in the R&D department will be reinvested in artificial intelligence, cloud services and automation technologies, Mr. Knudsen said.
Novo Nordisk (NOVOb.CO), the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States. Sales of Novo's new once-weekly Ozempic GLP-1 drug, which the Danish company hopes will take market share from Eli Lilly's (LLY.N) Trulicity, beat forecasts for the third quarter. Eli Lilly has been eating into Novo's previously fast-selling Victoza - a so-called GLP-1 drug that imitates an intestinal hormone to stimulate insulin production.
Novo Nordisk, the world's top maker of diabetes drugs, reported encouraging sales of its main growth drivers on Thursday as it announced more job cuts amid a restructuring to cope with intensifying pricing pressure in the United States. Sales of Novo's new once-weekly Ozempic GLP-1 drug, which the Danish company hopes will take market share from Eli Lilly's Trulicity, beat forecasts for the third quarter. Eli Lilly has been eating into Novo's previously fast-selling Victoza - a so-called GLP-1 drug that imitates an intestinal hormone to stimulate insulin production.
On a per-share basis, the Bagsvaerd, Denmark-based company said it had net income of 58 cents. The drugmaker posted revenue of $4.31 billion in the period. Novo Nordisk shares have fallen 19 percent since ...
Novo Nordisk A/S (NYSE: NVO ) releases its next round of earnings this Thursday, Nov. 1. Here's Benzinga's essential guide to Novo Nordisk's Q3 earnings report. Earnings and Revenue Wall Street expects ...
NEW YORK, Oct. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Wall Street analysts estimate that Novartis will report revenues of $13.4 billion during the fourth quarter of 2018, a 4.0% increase in year-over-year revenues as compared to $12.9 billion during the fourth quarter of 2017. The earnings-per-share is estimated at $1.29 during the fourth quarter of 2018. Analysts estimate the net income margin to increase to 22.1% during the fourth quarter of 2018 as compared to 21.8% during the fourth quarter of 2017.
Alcon, the eye care business of Novartis AG (NVS), includes surgical products and vision care products. Alcon reported revenues of ~$1.76 billion during the third quarter of 2018, a 3% increase in year-over-year (or YoY) revenues as compared to ~$1.71 billion in the third quarter of 2017. The growth was driven by a 5% growth in operating revenues, offset by a 2% negative impact of foreign exchange.
According to the GuruFocus All-in-One Screener, the following companies have high business predictability ratings and a wide margin of safety. Warning! GuruFocus has detected 3 Warning Signs with WLK. The company has a 3.5-star out of five business predictability rating and, according to the discounted cash flow calculator, a 54% margin of safety at $74 per share.
Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The Innovative Medicines business contributed over 67.2% of the total revenues for Novartis and saw 6% growth in year-over-year (or YoY) revenues to ~$8.6 billion during the third quarter of 2018.
In a lawsuit filed in federal court in Trenton, New Jersey, Minnesota Attorney General Lori Swanson took aim at the companies after the list price for some insulin products more than tripled since 2002. The lawsuit alleged that companies fraudulently set artificially high list price for their products while offering rebates to pharmacy benefit managers (PBMs) in exchange for them covering the drug on behalf of health plans.
Minnesota's attorney general on Tuesday filed a lawsuit accusing drug manufacturers Sanofi SA, Novo Nordisk and Eli Lilly and Co of deceptively raising prices for insulin. In a lawsuit filed in federal court in Trenton, New Jersey, Minnesota Attorney General Lori Swanson took aim at the companies after the list price for some insulin products more than tripled since 2002.
Novo Nordisk (NOVOb.CO) is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit. Novo, best known for its diabetes drugs, has been looking for biopharma assets after losing out to French rival Sanofi (SASY.PA) in the chase for Belgian biotech company Ablynx (ABLX.BR) in January. Sales at Novo's biopharma unit fell 16 percent last year and the Danish drugmaker said on Monday it has hired AstraZeneca's (AZN.L) head of cardiovascular and metabolic diseases, Ludovic Helfgott, to head the business from next April.
COPENHAGEN (Reuters) - Novo Nordisk might be able to complete an acquisition within its struggling biopharma business this year, its chief executive told Reuters on Monday. "It is not always easy ...
Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.
Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business
As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...